Stock Analysis, Dividends, Split History

XLRN / Acceleron Pharma Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)2,374.19
Enterprise Value ($M)2,298.28
Book Value ($M)333.11
Book Value / Share7.24
Price / Book7.14
NCAV ($M)280.68
NCAV / Share6.10
Price / NCAV8.47
Share Statistics
Common Stock Shares Outstanding 45,261,175
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 45,419,061
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.30
Return on Assets (ROA)-0.44
Return on Equity (ROE)-0.48
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio20.53
Income Statement (mra) ($M)
Reimbursement Revenue12,940,000.00
Operating Income-109.98
Net Income-108.45
Earnings Per Share Basic And Diluted-2.68
Earnings Per Share Basic-2.68
Earnings Per Share Diluted-2.68
Cash Flow Statement (mra) ($M)
Cash From Operations-76.73
Cash from Investing-64.37
Cash from Financing-64.37
Identifiers and Descriptors
Central Index Key (CIK)1280600
Related CUSIPS
00434H958 00434H908 000434H10

Split History

Stock splits are used by Acceleron Pharma Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related News Stories

Biotech Stocks Bloodied But Can Now Drive M&A

2018-10-19 seekingalpha
The biotech stocks plunge along with the broader market, as the smallcap and midcap biotech stocks retreat -17%. (41-2)

Celgene's Otezla Meets Goal in Scalp Plaque Psoriasis Study

2018-10-09 zacks
Celgene Corporation (CELG - Free Report) announced that the phase III study, STYLE, on plaque psoriasis drug, Otezla, met its primary endpoint. (4-0)

Movers and Shakers Oct. 1

2018-10-01 biospace
Second Genome -- South San Francisco-based Second Genome tapped Chief Scientific Officer Karim Dabbagh as its new president and chief executive officer. Dabbagh will replace Glenn Nedwin, who retired from the company. Prior to Second Genome, Dabbagh served as head of the immunoregulation department and external R&D innovation for autoimmune and inflammatory diseases at Pfizer. Before Pfizer, Dabbagh co-founded Modus BioMedicine, a start-up biotechnology company focused on treatments for transplantation and autoimmune disease. (19-3)

Geron's Stock Plunges as J&J Ends Imetelstat Collaboration

2018-09-28 zacks
Geron Corporation (GERN - Free Report) suffered a major setback as it announced that Janssen, a subsidiary of Johnson & Johnson (JNJ - Free Report) , has terminated the collaboration and license agreement related to development of Geron’s sole pipeline candidate, imetelstat. The termination is effective from Sep 28. (15-1)

Head-To-Head: Geron's Imetelstat Versus Acceleron's Luspatercept For MDS

2018-09-27 seekingalpha
Much attention has been focused on whether or not Jannsen will continue its partnership with Geron. (2-7)

CUSIP: 00434H108